CurrentNeighborhood Health Plan of Rhode IslandPolicy 2181-A

Tolvaptan (Samsca) for hyponatremia — Coverage Criteria

Covers use of tolvaptan (Samsca) for treatment of clinically significant hypervolemic and euvolemic hyponatremia when approval criteria are met; applies to members of Neighborhood Health Plan of Rhode Island per this policy.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyTolvaptan (Samsca) for hyponatremia — Coverage Criteria

Policy CodePolicy 2181-A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionRequest prior authorization for an initial 30-day approval when therapy was initiated in the hospital and baseline serum sodium met specified thresholds.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

30 daysmaximum initial authorization duration

<125serum sodium threshold for FDA-approved indication

<135alternative threshold when symptomatic

FDA-approvedapproved indication category

Coverage Criteria for Tolvaptan (Samsca)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Hypervolemic/Euvolemic hyponatremia — initial authorization

Covered when ALL of the following are met:

Initial inpatient authorization criteria: A. Therapy was initiated (or re-initiated) in the hospital for hypervolemic or euvolemic hyponatremia.

Serum sodium at initiation: B. Serum sodium was <125 mEq/L OR serum sodium was <135 mEq/L with symptoms (e.g., nausea, vomiting, headache, lethargy, confusion) at the time of therapy initiation.<125 mEq/L or <135 mEq/L with symptoms

Authorization duration limit: C. The member will not receive the requested drug continually for greater than 30 days.

Applies to hypervolemic or euvolemic hyponatremia, including heart failure and SIADH

Patients who require an urgent intervention to raise serum sodium to prevent or treat serious neurologic symptoms should not be treated with tolvaptan (Samsca). The policy explicitly states that tolvaptan is not appropriate when rapid correction is needed for severe neurologic compromise and that benefit for such use has not been established.

All indications not specifically listed in this policy (that is, uses beyond the FDA‑approved and recognized compendial indications) are considered experimental/investigational and not medically necessary for coverage under this policy.

Use of tolvaptan for indications other than the FDA‑approved treatment of clinically significant hypervolemic and euvolemic hyponatremia (including off‑label uses) is considered not medically necessary/experimental and is excluded from coverage.

Provider Requirements and Authorization Rules

Prior Authorization

Prior authorization: initial 30-day approval

Prior authorization for tolvaptan (Samsca) is limited to an initial 30-day approval when therapy is initiated or re-initiated in the hospital and baseline sodium criteria are met. Authorization beyond 30 days is not granted under this initial hospital-start pathway.

Auth limited to 30 days when therapy is initiated or re-initiated in the hospital
Baseline serum sodium <125 mEq/L OR <135 mEq/L with symptoms at time of initiation
Member must not receive the drug continually for >30 days under this pathway

Denial Risk

Urgent correction contraindication

Tolvaptan should not be used when urgent correction of serum sodium is required to prevent or treat serious neurologic symptoms. In such cases, alternative urgent interventions should be employed because tolvaptan has not been established to provide rapid symptomatic benefit and is contraindicated for urgent neurologic correction.

Contraindicated when urgent rise in serum sodium is needed to prevent/treat serious neurologic symptoms

Documentation Required

Conservative therapy prior to use

Conservative measures must be attempted and documented before tolvaptan is used for hyponatremia. This includes efforts such as fluid restriction and other appropriate non-pharmacologic or standard medical measures, with documentation of inadequate response or intolerance prior to initiation.

Documented trial of fluid restriction with inadequate response OR intolerance
Documentation of other conservative measures attempted, as applicable

Documentation Required

Required clinical documentation

Required clinical documentation must include evidence that therapy was initiated or re-initiated in the hospital, baseline serum sodium at the time of initiation, and documentation of symptoms when sodium is between 125–134 mEq/L. Also document that the member will not be treated continuously >30 days under the hospital-initiation pathway.

Confirmation therapy was initiated/re-initiated in the hospital
Baseline serum sodium value at initiation
If sodium <135 mEq/L and ≥125 mEq/L, documentation of symptoms (e.g., nausea, vomiting, headache, lethargy, confusion)
Plan confirming treatment will not be continual for >30 days under this authorization

Key Definitions

Clinically significant hyponatremia — definition and qualifying criteria

DefinitionClinically significant hyponatremia: serum sodium <125 mEq/L, or less marked hyponatremia (<135 mEq/L) that is symptomatic and has resisted correction with fluid restriction.

Examples of symptomsSymptoms may include nausea, vomiting, headache, lethargy, confusion (used to qualify <135 mEq/L cases)

Relation to FDA indicationIndication applies to hypervolemic and euvolemic hyponatremia, including heart failure and SIADH

Contraindication notePatients requiring urgent intervention to raise serum sodium for serious neurologic symptoms should not be treated with tolvaptan/Samsca

OpenPayer

Tolvaptan (Samsca) for hyponatremia — Coverage Criteria

Coverage Criteria for Tolvaptan (Samsca)

Drug and Clinical Coding

Provider Requirements and Authorization Rules

Key Definitions

Background